Nektar Therapeutics logo

Nektar TherapeuticsNASDAQ: NKTR

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

03 May 1994

Next earnings report:

04 March 2025

Last dividends:

N/A

Next dividends:

N/A
$184.46 M
-93%vs. 3y high
53%vs. sector
-vs. 3y high
-vs. sector
-32%vs. 3y high
74%vs. sector
-93%vs. 3y high
38%vs. sector

Price

after hours | Wed, 20 Nov 2024 21:25:15 GMT
$1.00-$0.03(-2.91%)

Dividend

No data over the past 3 years
$24.12 M$31.39 M
$24.12 M-$37.06 M

Analysts recommendations

Institutional Ownership

NKTR Latest News

Multiple Catalysts Ahead For Nektar Therapeutics
seekingalpha.com14 November 2024 Sentiment: POSITIVE

Nektar continues to make progress with rezpegaldesleukin, with results from the phase 2 atopic dermatitis study expected in H1'25. NKTR-255 is showing promising results in multiple oncology trials, although these are only small studies. NKTR-255 also has a potential near-term readout in the JAVELIN Bladder Medley study, although there is competition.

Nektar Q3 Loss Narrower Than Expected, Pipeline Development in Focus
zacks.com08 November 2024 Sentiment: POSITIVE

NKTR reports encouraging third-quarter results as both earnings and revenues beat estimates. Product sales increase year over year.

Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates
zacks.com07 November 2024 Sentiment: POSITIVE

Nektar Therapeutics (NKTR) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.19 per share a year ago.

Nektar Therapeutics Reports Third Quarter 2024 Financial Results
prnewswire.com07 November 2024 Sentiment: NEUTRAL

SAN FRANCISCO , Nov. 7, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2024. Cash and investments in marketable securities on September 30, 2024 were $249.0 million as compared to $329.4 million at December 31, 2023.

Nektar Therapeutics to Participate in Upcoming Investor Conferences
prnewswire.com06 November 2024 Sentiment: POSITIVE

SAN FRANCISCO , Nov. 6, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the upcoming conferences: UBS Global Healthcare Conference in Rancho Palos Verdes, CA on Wednesday, November 13, 2024 at 1:15 p.m. Eastern Time / 10:15 a.m.

Nektar to Announce Financial Results for the Third Quarter 2024 on Thursday, November 7, 2024, After Close of U.S.-Based Financial Markets
prnewswire.com31 October 2024 Sentiment: POSITIVE

SAN FRANCISCO , Oct. 31, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2024 on Thursday, November 7, 2024, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m.

Nektar Announces Publication in Nature Communications of Results from Phase 1b Studies of Rezpegaldesleukin in Two Inflammatory Skin Diseases
prnewswire.com29 October 2024 Sentiment: POSITIVE

- Data from multiple Phase 1b studies in inflammatory skin conditions demonstrate durable dose-dependent improvements in physician-assessed disease activity and patient-reported outcomes - - Biomarker analyses demonstrate plurality of Treg-mediated pathways with potential effect on tissue resident memory T cell populations resulting in sustained efficacy seen in the antigen challenged mouse model and in clinical trials - SAN FRANCISCO , Oct. 29, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), today announced the publication of peer-reviewed data from two Phase 1b studies in Nature Communications highlighting the efficacy, safety, and tolerability of rezpegaldesleukin in patients with atopic dermatitis (AD) and psoriasis (PsO). Rezpegaldesleukin is a first-in-class interleukin-2 receptor (IL-2R) agonist that enhances the activity of regulatory T cells (Tregs) with promising dose-dependent clinical activity across multiple physician-assessed and patient-reported endpoints for AD and PsO.

Nektar Announces Publication in Blood of Phase 1 Data for Novel IL-15 Agonist NKTR-255 in Combination with Autologous CD19-22 CAR-T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia
prnewswire.com17 October 2024 Sentiment: POSITIVE

– Relapse-free/progression-free survival for NKTR-255 plus CD19-22 CAR-T cell therapy at 12 months was double that of historical controls (67% vs 38%) – – Eight of nine patients achieved complete remission, all without detectable MRD – SAN FRANCISCO , Oct. 17, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of the first clinical data from a Phase 1 study evaluating NKTR-255 in combination with an autologous bispecific chimeric antigen receptor (CAR)-T cell therapy targeting CD19 and CD22 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) in Blood, the peer-reviewed medical journal of the American Society of Hematology. NKTR-255 is a novel IL-15 receptor agonist currently being studied in clinical trials in combination with cellular therapies and immune checkpoint inhibitors.

Nektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV 2024
prnewswire.com25 September 2024 Sentiment: POSITIVE

- New proteomic analyses show that rezpegaldesleukin increases the protein levels of immune-regulating pathways while reducing specific serum proteins known to be elevated in patients with atopic dermatitis - SAN FRANCISCO , Sept. 25, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced several presentations for rezpegaldesleukin (REZPEG) at the 2024 European Academy of Dermatology and Venereology (EADV) Congress.

What Makes Nektar (NKTR) a New Buy Stock
zacks.com13 August 2024 Sentiment: POSITIVE

Nektar (NKTR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • 1(current)
  • 2

What type of business is Nektar Therapeutics?

Nektar Therapeutics is a research biopharmaceutical company. Founded in 1990 in California. Currently registered in Delaware in 1998. The company's activities are focused on the development of innovative drugs. Research and development include potential methods for treating cancer and autoimmune diseases. In the field of immuno-oncology, drugs are being developed to stimulate and support the body's immune response to fight cancer. The biological drug bempegaldesleukin (NKTR-214) is the main development in this area. In the treatment of autoimmune diseases, the company is developing the drug NKTR-358. The drug has undergone trials for the treatment of systemic lupus erythematosus, psoriasis, and atopic dermatitis. MOVANTIK is a drug for the treatment of constipation caused by opioids, a side effect of chronic use of prescription opioid analgesics.

What sector is Nektar Therapeutics in?

Nektar Therapeutics is in the Healthcare sector

What industry is Nektar Therapeutics in?

Nektar Therapeutics is in the Biotechnology industry

What country is Nektar Therapeutics from?

Nektar Therapeutics is headquartered in United States

When did Nektar Therapeutics go public?

Nektar Therapeutics initial public offering (IPO) was on 03 May 1994

What is Nektar Therapeutics website?

https://www.nektar.com

Is Nektar Therapeutics in the S&P 500?

No, Nektar Therapeutics is not included in the S&P 500 index

Is Nektar Therapeutics in the NASDAQ 100?

No, Nektar Therapeutics is not included in the NASDAQ 100 index

Is Nektar Therapeutics in the Dow Jones?

No, Nektar Therapeutics is not included in the Dow Jones index

When was Nektar Therapeutics the previous earnings report?

No data

When does Nektar Therapeutics earnings report?

The next expected earnings date for Nektar Therapeutics is 04 March 2025